Study | Exclusion reasons | Rmk | Reference |
---|---|---|---|
Dwarakanath (control exposed to MMI), 1999 | inadequate or absent control group | EXCLUDED: no adequate control group: methimazole/neomercazole known to be a teratogen. | |
Andersen 2013 (control unexposed, disease free), 2013 | repeat population groups, duplicate reports (most recent study included) | EXCLUDED: Andersen 2019 published an update analysis of this study Andersen 2013 based on a longer period and including more participants. |
Andersen J. Clin. Endocrinol. Metab. 2013; 98:4373-81 10.1210/jc.2013-2831 |
Andersen 2013 (control unexposed, sick), 2013 | repeat population groups, duplicate reports (most recent study included) | EXCLUDED: Andersen 2019 published an update analysis of this study Andersen 2013 based on a longer period and including more participants. |
Andersen J. Clin. Endocrinol. Metab. 2013; 98:4373-81 10.1210/jc.2013-2831 |
Andersen 2013 (control exposed to MMI/CMZ), 2013 | repeat population groups, duplicate reports (most recent study included) | EXCLUDED: Andersen 2019 published an update analysis of this study Andersen 2013 based on a longer period and including more participants. |
Andersen J. Clin. Endocrinol. Metab. 2013; 98:4373-81 10.1210/jc.2013-2831 |
Andersen 2014 (control exposed to MMI), 2014 | repeat population groups, duplicate reports (most recent study included) | EXCLUDED: Andersen 2019 published an update analysis of this study Andersen 2014 based on a longer period and including more participants. | |
Andersen 2014 (control unexposed, disease free), 2014 | repeat population groups, duplicate reports (most recent study included) | EXCLUDED: Andersen 2019 published an update analysis of this study Andersen 2014 based on a longer period and including more participants. | |
Andersen 2014 (control unexposed, sick), 2014 | repeat population groups, duplicate reports (most recent study included) | EXCLUDED: Andersen 2019 published an update analysis of this study Andersen 2014 based on a longer period and including more participants. | |
Momotani, 1977 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: no distinction between MMI and PTU exposure. |
Momotani Nihon Naibunpi Gakkai Zasshi 1977; 53:1148-58 10.1507/endocrine1927.53.10_1148 |